Jazz Pharmaceuticals(JAZZ)

CA - Palo AltoPharmaceutical10 H-1B visas (FY2023)

Focus: Jazz Pharmaceuticals is a public specialty pharmaceutical company focused on neurology and small-molecule therapeutics, generating $3.8B in annual revenue with significant exposure to cannabinoid and sleep-disorder franchises.

Neurology

Profile data last refreshed 6h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Jazz Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Jazz Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

6/9 — Partial

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$3.8B

Key Products

EPIDIOLEX

Epilepsy

$197M Part D

Peak14.6yr

Flagship product representing 42% of company revenue; faces long-term patent cliff risk in 2041 despite strong current sales.

Help build intelligence for Jazz Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Established $3.8B revenue base with demonstrated profitability ($415M net income in FY2025), offering career stability rare in biotech.
Significant R&D acceleration (43% YoY increase in spend from $590M to $850M) signals commitment to pipeline depth and innovation across neurology and oncology.
Perfect H1B track record (10 approvals, 0 denials in 2023) and 100% visa sponsorship approval rate demonstrates genuine commitment to global talent recruitment.

Watch Out For

Extreme revenue concentration (42% from single product EPIDIOLEX) creates existential exposure to Epidiolex patent cliff in 2041 and competitive generic entry risk.
Current hiring freeze (zero active job postings despite $3.8B revenue and 43% R&D spend growth) suggests internal restructuring or temporary talent pause despite financial strength.

Generated by Claude from Jazz Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

XYWAV

Narcolepsy/Sleep disorders

$169M Part D

Peak14.5yr

Second-largest revenue driver; successor formulation to XYREM with extended LOE through 2041.

XYREM

Narcolepsy

$98M Part D

Peak7.1yr

Legacy product being transitioned to XYWAV; faces patent cliff by 2033 as patients migrate to newer formulation.

ZEPZELCA

Small-cell lung cancer

$2M Part D

Peak13.7yr

Oncology entry with modest current uptake; LOE protection extends to 2040.

ZIIHERA

HER2-expressing gastric cancer

Growth

Bispecific HER2-directed antibody in growth phase; represents emerging oncology franchise differentiation.

RYLAZE

Acute lymphoblastic leukemia

Peak

Oncology biologic addressing asparagine depletion; niche but defensible indication.

VYXEOS

Acute myeloid leukemia

Peak6.7yr

Oncology combination therapy with LOE protection through 2033; contributor to AML franchise growth.

LUVOX

OCD

LOE Approaching

Legacy psychiatric medication facing imminent patent erosion; represents legacy portfolio wind-down.

FAZACLO ODT

Treatment-resistant schizophrenia

LOE Approaching

Specialized antipsychotic in LOE phase; niche market with declining revenue trajectory.

LUVOX CR

OCD

LOE Approaching

Extended-release psychiatric formulation approaching LOE; legacy portfolio rationalization candidate.

Pipeline & Clinical Trials

Epidiolex

Seizures

N/A

Clinical Trials (1)

NCT05772429Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting

N/A

ONC201

Glioma

N/A

Clinical Trials (1)

NCT04617002Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

N/A

Delphi Consensus Excessive Daytime Sleepiness in OSA

Obstructive Sleep Apnea

N/A

Clinical Trials (1)

NCT05055271Delphi Consensus Excessive Daytime Sleepiness in OSA

N/A

CPX-351

Secondary AML

N/A

Clinical Trials (1)

NCT02533115EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML

N/A

Language of Sleepiness

Sleep

N/A

Clinical Trials (1)

NCT04323254Language of Sleepiness

N/A

A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy

Narcolepsy

N/A

Clinical Trials (1)

NCT02769780A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy

N/A

Erwinia L-asparaginase

Leukemia, Acute Lymphoblastic

N/A

Clinical Trials (1)

NCT00590915Erwinase Master Treatment Protocol

N/A

Zepzelca

Extensive-stage Small-cell Lung Cancer

N/A

Clinical Trials (1)

NCT04894591To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

N/A

Zanidatamab

HER2-Positive Advanced Biliary Tract Cancer

N/A

Clinical Trials (1)

NCT04578444An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

N/A

Ultrasound Elastography

Bone Marrow Transplant Complications

N/A

Clinical Trials (1)

NCT03865589Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome

N/A

CMX001

Outcomes

N/A

Clinical Trials (1)

NCT02167685The Chimerix CMX001 Registry

N/A

ONC201

Glioma

N/A

Clinical Trials (1)

NCT03134131Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

N/A

ONC201

Glioma

N/A

Clinical Trials (1)

NCT05392374Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

N/A

Asparaginase Erwinia Chrysanthemi

Acute Lymphoblastic Leukemia

N/A

Clinical Trials (1)

NCT04943952JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase

N/A

Brincidofovir

Adenovirus

N/A

Clinical Trials (1)

NCT02420080A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304

N/A

Epidiolex 100 mg/mL Oral Solution

Lennox Gastaut Syndrome

N/A

Clinical Trials (1)

NCT05485831Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

N/A

There are no interventions in this study. All participants complete online surveys.

Lung Cancer Patients

N/A

Lurbinectedin

Small Cell Lung Cancer

N/A

Clinical Trials (1)

NCT04291937A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA

N/A

Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopo

Adenovirus Infections, Human

N/A

Clinical Trials (1)

NCT04285788Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients

N/A

Sleep study

Hypersomnia

N/A

Clinical Trials (1)

NCT05850676Disentangling the Role of Depression in Hypersomnia

N/A

Child and Adolescent Registry for Participants With Narcolepsy

Narcolepsy

N/A

Clinical Trials (1)

NCT04899947Child and Adolescent Registry for Participants With Narcolepsy

N/A

Epidiolex

Maternal Complications

N/A

Clinical Trials (1)

NCT06113237Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy

N/A

Track 1

Daytime Sleepiness

N/A

Clinical Trials (1)

NCT04176042Community-Level Daytime Sleepiness: Social-Environmental Determinants, Consequences, and Impact of Sleep Apnea

N/A

European VOD Registry

Hepatic Veno-Occlusive Disease

N/A

Clinical Trials (1)

NCT03032016European VOD Registry

N/A

CPX-351

Acute Myeloid Leukemia

N/A

Clinical Trials (1)

NCT05169307CPX-351 Real-World Effectiveness and Safety Study

N/A

Transition from Xyrem to Xywav

Narcolepsy

N/A

Clinical Trials (1)

NCT04803786A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy

N/A

Sativex®

Multiple Sclerosis

N/A

Clinical Trials (1)

NCT02073474An Observational Post-Marketing Safety Registry of Sativex®

N/A

Vyxeos liposomal

Acute Myeloid Leukemia (AML)

N/A

Clinical Trials (1)

NCT06143839VYxeoS Liposomal Italian Observational Study iN the Real Practice

N/A

CPX-351

Acute Myeloid Leukemia With Myelodysplasia-Related Changes

N/A

Clinical Trials (1)

NCT03526926A Post-Marketing Observational Study of VYXEOS™

N/A

Cannabidiol

Epilepsy

N/A

Clinical Trials (1)

NCT02660255Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy

N/A

Ziconotide

Patients With Severe Chronic Pain

N/A

Clinical Trials (1)

NCT01888120Patient Registry of Intrathecal Ziconotide Management(PRIZM)

N/A

Brincidofovir

Adenovirus

N/A

Clinical Trials (1)

NCT02596997Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

N/A

CPX-351

Acute Myelogenous Leukemia

PHASE_1

Clinical Trials (1)

NCT00875693A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)

Phase 1

Erwinase

Acute Lymphoblastic Leukemia

PHASE_1

Sativex

Evaluation of Abuse Potential of Sativex

PHASE_1

Clinical Trials (1)

NCT01323569Abuse Potential of Sativex

Phase 1

Erwinia Chrysanthemi asparaginase

Acute Lymphoblastic Leukemia (ALL)

PHASE_1

Clinical Trials (1)

NCT02647190Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Phase 1

Paclitaxel

Ovarian Cancer

PHASE_1

Clinical Trials (1)

NCT05636111Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Phase 1

Sativex®

Healthy Subjects

PHASE_1

Clinical Trials (1)

NCT02325011An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.

Phase 1

Sativex

Food Effect

PHASE_1

Clinical Trials (1)

NCT01322464Study to Assess Food Effect on Sativex Bioavailability

Phase 1

CPX-351

Hematologic Neoplasms

PHASE_1

Clinical Trials (1)

NCT00389428Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.

Phase 1

CMX157

Healthy

PHASE_1

Clinical Trials (1)

NCT01080820A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers

Phase 1

CPX-351

Acute Myeloid Leukemia

PHASE_1

Clinical Trials (1)

NCT03878927CPX-351+GO in Subjects 55 Years Old, or Older, With AML

Phase 1

Lurbinectedin

Extensive Stage Lung Small Cell Carcinoma

PHASE_1

Clinical Trials (1)

NCT05244239Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer

Phase 1

Vyxeos

Acute Myeloid Leukemia

PHASE_1

Clinical Trials (1)

NCT05558124CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Phase 1

JZP441

Healthy Participants

PHASE_1

Clinical Trials (1)

NCT05651152A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants

Phase 1

ONC206

Diffuse Midline Glioma (DMG)

PHASE_1

CMX001

Healthy

PHASE_1

Clinical Trials (1)

NCT00780182Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers

Phase 1

JZP441

Narcolepsy

PHASE_1

Clinical Trials (1)

NCT06961266A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

Phase 1

CPX-351

Hematologic Malignancy

PHASE_1

Clinical Trials (1)

NCT03555955A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

Phase 1

Sativex

Hepatic Impairment

PHASE_1

Clinical Trials (1)

NCT01887301Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 11 approved products, 147 clinical trials

Top TAs: Oncology, Neurology, Rare Diseases

H-1B (2023): 10 approvals

Publications: 34 in PubMed

SEC Filings: 2 available

Portfolio Health

Growth1 (9%)

Peak7 (64%)

LOE Approaching3 (27%)

11 total products

Therapeutic Area Focus

Oncology

4 marketed94 pipeline

Neurology

2 marketed55 pipeline

Rare Diseases

1 marketed9 pipeline

Gastroenterology

1 marketed8 pipeline

Financials (FY2025)

Revenue

$3.8B5%

R&D Spend

$850M(22%)44%

Net Income

$415M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study.

CNS drugs

2026

PMID:41831073

Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial.

asparaginase erwinia chrysanthemi (recombinant)-rywn

INTRAMUSCULAR · INJECTABLE

1 marketed3 pipeline

Psychiatry

3 marketed

Annals of oncology : official journal of the European Society for Medical Oncology

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Jazz Pharmaceuticals(JAZZ)

About Jazz Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (9)

Key Products by Revenue

Other Products (5)

Pipeline & Clinical Trials

Recent News · Jazz Pharmaceuticals(10)

Open Jobs (0)

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Research Publications(10)